Liraglutide: Benefits & Research
Part of the Liraglutide Complete Guide
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
Weight Loss
The SCALE trial program demonstrated liraglutide 3.0 mg (Saxenda) produces approximately 8% mean body weight loss over 56 weeks. While less than semaglutide's 15–17%, liraglutide was the first GLP-1 agonist approved specifically for obesity and has extensive real-world safety data.
Cardiovascular Benefits
The LEADER trial demonstrated 13% reduction in major adverse cardiovascular events (MACE) in type 2 diabetes patients. This established cardiovascular safety and benefit for the GLP-1 agonist class and contributed to liraglutide's broad clinical adoption.
Glucose Control
Liraglutide reduces HbA1c by 1.0–1.5% in type 2 diabetes, with the glucose-dependent insulin mechanism minimizing hypoglycemia risk. It also reduces fasting and postprandial glucose through glucagon suppression and delayed gastric emptying.